Ibe Susumu, Kishimoto Yoshimi, Niki Hanako, Saita Emi, Umei Tomohiko, Miura Kotaro, Ikegami Yukinori, Ohmori Reiko, Kondo Kazuo, Momiyama Yukihiko
Department of Cardiology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Endowed Research Department "Food for Health", Ochanomizu University, Tokyo, Japan.
Heart Vessels. 2019 Jun;34(6):965-970. doi: 10.1007/s00380-018-01328-3. Epub 2019 Jan 1.
Nesfatin-1 is a recently identified anorexigenic peptide mainly secreted from the brain and adipose tissue. Although nesfatin-1 may have pro-inflammatory and apoptotic properties, the association between plasma nesfatin-1 levels and coronary artery disease (CAD) has not been clarified yet. We investigated plasma nesfatin-1 levels in 302 patients undergoing elective coronary angiography. Of the 302 study patients, CAD was present in 172 (57%), of whom 67 had 1-vessel, 49 had 2-vessel, and 56 had 3-vessel disease. Compared with 130 patients without CAD, 172 with CAD had higher plasma nesfatin-1 levels (median 0.21 vs. 0.17 ng/mL, P < 0.01). A stepwise increase in nesfatin-1 levels was found depending on the number of > 50% stenotic coronary vessels: 0.17 in CAD(-), 0.20 in 1-vessel, 0.21 in 2-vessel, and 0.22 ng/mL in 3-vessel disease (P < 0.05). A high nesfatin-1 level (> 0.19 ng/mL) was found in 43% of patients with CAD(-), 55% of those with 1-vessel, 55% of those with 2-vessel, and 68% of those with 3-vessel disease (P < 0.05). Nesfatin-1 levels significantly correlated with the number of > 50% stenotic coronary segments (r = 0.14, P < 0.02). In multivariate analysis, plasma nesfatin-1 levels were a significant factor for CAD independent of atherosclerotic risk factors. The odds ratio for CAD was 1.71 (95% CI 1.01-2.91) for high nesfatin-1 level of > 0.19 ng/mL (P < 0.05). Thus, plasma nesfatin-1 levels were found to be high in patients with CAD and were associated with CAD independent of atherosclerotic risk factors, suggesting that high nesfatin-1 levels in patients with CAD may play a role in the development of coronary atherosclerosis.
Nesfatin-1是一种最近发现的厌食肽,主要由大脑和脂肪组织分泌。尽管Nesfatin-1可能具有促炎和凋亡特性,但血浆Nesfatin-1水平与冠状动脉疾病(CAD)之间的关联尚未明确。我们调查了302例行择期冠状动脉造影患者的血浆Nesfatin-1水平。在302例研究患者中,172例(57%)患有CAD,其中67例为单支血管病变,49例为双支血管病变,56例为三支血管病变。与130例无CAD的患者相比,172例CAD患者的血浆Nesfatin-1水平更高(中位数0.21 vs. 0.17 ng/mL,P < 0.01)。发现Nesfatin-1水平根据>50%狭窄冠状动脉血管数量呈逐步升高:CAD(-)组为0.17,单支血管病变组为0.20,双支血管病变组为0.21,三支血管病变组为0.22 ng/mL(P < 0.05)。CAD(-)组43%、单支血管病变组55%、双支血管病变组55%、三支血管病变组68%的患者Nesfatin-1水平较高(P < 0.05)。Nesfatin-1水平与>50%狭窄冠状动脉节段数量显著相关(r = 0.14,P < 0.02)。在多变量分析中,血浆Nesfatin-1水平是CAD的一个独立于动脉粥样硬化危险因素的显著因素。Nesfatin-1水平>0.19 ng/mL时CAD的比值比为1.71(95%CI 1.01 - 2.91)(P < 0.05)。因此,发现CAD患者血浆Nesfatin-1水平较高,且与CAD独立于动脉粥样硬化危险因素相关,提示CAD患者中较高的Nesfatin-1水平可能在冠状动脉粥样硬化的发展中起作用。